The FDA agreed to a multicomponent assessment using four subdomains for the key secondary endpoint on cognition and behavior.
All 162 enrolled patients remain active in the EMPEROR Phase III trial.
Top 50 sites treat half of addressable U.S. Dravet syndrome patients.
On its third-quarter 2026 business update call, held on Oct. 29, 2026, Stoke Therapeutics (NASDAQ:STOK) announced alignment with the FDA on a composite endpoint for lead drug candidate Zorevunersen in Dravet syndrome. This regulatory agreement clarifies the approval pathway for the experimental medicine, which targets a rare genetic epilepsy with high unmet medical need. For long-term investors, clear clinical endpoints and full trial retention strengthen prospects for potential approval and launch in early 2028.
Three things management said stand out.
The New Drug Application (NDA) submission for Zorevunersen, an investigational therapy for Dravet syndrome, will use a combined cognitive and behavioral assessment. The Food and Drug Administration (FDA) agreed to evaluate key secondary endpoints using four subdomains from Vineland-3, an adaptive behavior scale.
An important outcome of our meeting was the FDA's willingness to accept a multicomponent assessment of Vineland-3 data for purposes of evaluating the key secondary endpoint related to changes in cognition and behavior.
-- Ian Smith, Chief Executive Officer
In the EMPEROR Phase III registrational trial, 162 patients enrolled across global sites without a single participant dropping out. High patient retention preserves statistical power and signals strong caregiver commitment to the clinical program.
We ultimately enrolled 162 patients. And as I mentioned, there have been no discontinuations to date. These metrics reflect a well-designed trial, the need for better treatments, and a deeply committed community of investigators, site teams, and caregivers.
-- Dr. Barry Ticho, Chief Medical Officer
Management identified 6,000 addressable pediatric patients in the U.S. living with Dravet syndrome. Half of those patients receive treatment at 50 specialized medical centers experienced in intrathecal delivery, an injection directly into the spinal canal.
Approximately half of identified U.S. patients are cared for by the top 50 sites. All 50 of those sites are experienced in administering intrathecal medicines and over half of these sites have participated in a zorevunersen study.
-- Jason Hoitt, Chief Patient Officer
Clinical progress extends into autosomal dominant optic atrophy, an inherited disorder causing vision loss. Phase I dosing for STK-002 tests whether targeting protein deficiency translates into improved sight.
OSPREY is designed to provide clinical proof of concept by testing whether increasing OPA1 protein expression with STK-002 translates into measurable effects on visual function in patients with ADOA.
-- Dr. Barry Ticho, Chief Medical Officer
Cash reserves of $358.8 million and partner reimbursements provide multiyear funding through expected commercial launch.
Along with the reimbursement we received from Biogen for zorevunersen-related expenses and a potential development milestone payment, we expect our cash position to fund our operations into early 2028.
-- Thomas Leggett, Chief Financial Officer
Before you buy stock in Stoke Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Stoke Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.